ALL WALES PRESCRIBING ADVISORY GROUP

MINUTES OF MEETING HELD
Thursday 7th July 2011 at 10.30am
At the St Michael’s Centre, 10a Pen Y Pound, Abergavenny,
NP7 5UD

Members
Dr Tessa Lewis (Chair) GP South East Wales
Ms Sue Beach Pharmacist
Ms Sian Evans Public Health Wales
Mr Paul Fleming Technical Director BGMA
Mr Richard Greville Director, ABPI Wales (non-voting)
Mrs Sarah Isaac Pharmacist
Dr Susannah Jacks GP
Dr Sue Jeffs Secondary Care Consultant
Ms Katie Panton ABPI Industry Representative
Dr Hamsaraj Shetty Secondary Care Consultant
Mr Jonathan Simms Pharmacist
Mr John Terry Secondary Care Pharmacist
Mrs Fiona Walker Pharmacist
Dr Mark Walker GP
Dr David Webb Secondary Care Consultant
Dr Sean Young GP

In attendance
Mr Trevor Brooking (Welsh Medicines Partnership)
Mrs Sue Cervetto (Welsh Medicines Partnership)
Mr Jamie Hayes (Welsh Medicines Partnership)
Mrs Karen Samuels (Welsh Medicines Partnership)

Key of abbreviations
AWMSG All Wales Medicines Strategy Group
AWPAG All Wales Prescribing Advisory Group
CASPA Comparative Analysis System for Prescribing Audit
CEPP Clinical Effectiveness Prescribing Programme
    (formerly known as the Prescribing Incentive Scheme)
CPW Community Pharmacy Wales
DGH District General Hospital
DoH Department of Health
1. Welcome and introduction
The Chair opened the meeting, welcomed members, and reminded those present of the remit of the Group.

2. Apologies
Mrs Jane Barnard
Mrs Nuala Brennan
Mr Bill Duffield
Mr Dave Hopkins
Mrs Louise Howard-Baker
Ms Robyn Miles
Dr Ashok Rayani
Mr Warwick Smith
Mrs Judith Vincent

3. Declarations of interest
There were no declarations of interest

4. Minutes of previous AWPAG meeting
The minutes of the previous meeting were checked for accuracy. There were none.

Matters arising:
Page 4, Item 7 – Antimicrobial Prescribing in Wales
The Chairman gave a verbal update regarding the establishment of a Task and Finish Group.

5. Analgesics Patient Information leaflet
The Chairman explained the background and thanked Dr Sue Jeffs and Dr Susanna Jacks for their input into the document. The leaflet and its content were discussed and changes were noted by the authors. Members agreed that the leaflet was not promotional.

It was suggested that a cautionary note should be included regarding other over the counter medicines that contain pain relieving formulae such as cold and flu remedies etc. Members considered medical terminology and readability. A proposal was made that a user survey be undertaken after endorsement to establish impact.
ACTION
Members to send any further comments/recommendations to Sue Jeffs
Sue Jeffs and Susanna Jacks to pilot an updated draft and present at the next meeting of AWPAG

7. Monitored Dosage Systems (MDS) - Data Collection
The Chairman explained the background and invited members to consider the data from Hywel Dda and Aneurin Bevan. It was agreed that a key factor was the use of MDS by hospital pharmacies. Hamsaraj Shetty agreed to provide secondary care data from within ABMU Health Board for comparison. Concern was expressed that due to the low number of responses the data could be seen as selective. It was noted that the data collections provided an indication of the numbers of patients involved both in primary and secondary care. The issue of 7 day and 28 day prescriptions was raised. It was agreed that this was dependent on the liaison between hospitals/GPs and community pharmacists and advice has been issued by GPC Wales. It was suggested that national standards for MDS should be produced. It was suggested that the data and questionnaires could be shared with colleagues in Northern Ireland who are undertaking a similar data collection. This was agreed subject to approval of the Hywel Dda medicines management team. The authors thanked Jill Craig and her colleagues in Bridgend for supplying data and information for the audit.

ACTION
All 3 data reports to be combined into a single document which includes national standards where appropriate
AWPAG new document to be discussed at AWMSG Steering Committee

8. Draft proposal on the prescribing status of Dronedarone
The Chairman presented the paper which was developed following the recent Welsh Interface Pharmacists meeting on 1st July 2011. This outlined Drug Safety Update advice and assessed dronedarone against the AWMSG shared care criteria. The group then discussed the “shared care” status for the medicine in NHS Wales. The Director of ABPI Wales asked that the manufacturer be consulted before the proposal is sent to the service for consultation. This was agreed.

The group voted and recommended that dronedarone be hospital only prescribed for a minimum of six months and suitable for shared care prescribing thereafter.

It was suggested that the consultation document includes CASPA prescribing data. It was suggested that ‘shared care’ may include rapid access for specialist review rather than an obligatory annual review in some regions.

ACTION
Mark Walker, Susanna Jacks and Sean Young to provide comment on the protocol
Chairman to discuss the recommendation with the manufacturer prior to consultation with cardiologists and LMCs in Wales
WMP to formalise the process for assessing shared care status and consulting with the industry

9. Patient Information at the Point of Discharge
The patient representative had been unable to attend the meeting. The Chairman gave an update and presented feedback from questionnaires sent to Health Boards. It was noted that the patient held medication record fits with work underway by CPW. A member questioned whether the use of leaflets was effective and this was discussed
briefly. John Terry provided the background to the work he and Jane Barnard had undertaken. A member suggested that AWMSG publish “standards” that could be locally adapted for use. It was noted that the creation of an electronic patient version of discharge medication would support this work and would be feasible with the introduction of electronic discharge systems. The ABPI representative raised the issue of “medical literacy” when compiling patient leaflets. The group were informed that MHRA were currently developing a standard template for patient information leaflets for use by the industry. It was suggested that the group liaise with Anne Hinchliffe at Public Health Wales as she is currently working on a similar project. The group welcomed the work and agreed the development of standards.

**ACTION**

Chairman to liaise with Anne Hinchliffe, Public Health Wales  
WMP to update template for use by NHS Wales and include recommendations for IT support

10. **NICE Quality Standards**  
The Chairman referred members to the discussion paper containing examples of current NICE Quality Standards. It was noted that the AWMSG Steering Committee had asked that AWPAG consider their use in Wales. The Chairman noted the comments and agreed to report back to the Steering Committee.

**ACTION**  
Chairman to update AWMSG Steering Committee

11. **CEPP Review - National Indicators 2011/12**  
The Chairman gave an update regarding the different general practice QoF prescribing components and CEPP. Feedback was provided from the MMPB meeting regarding the QP and AWMSG National Indicators. It was confirmed that the period of measurement for QP will be Jan–March 2012. The group agreed that AWMSG indicators and QP indicators should be aligned with baseline measure December and targets set according to national practice ranking rather than locality. It was noted that in light of the Category M status of resdronate, caution was needed in using the QIPP indicator, “Number of prescription items for alendronic acid (sodium alendronate) as a % of the total number of prescription items for biphosphonates and other drugs affecting bone metabolism (BNF 6.6.2)”

12. **CEPP Review – National Indicators 2012/13**  
The Chairman asked the group to consider indicators for 2012/13. It was agreed that dosulepin should be retained for another year. A number of suggestions were made for further consideration by the Task and Finish Group including tramadol, Opioids against morphine, Glucose Monitoring Strips, SLS and ACBS, Items of limited value, contraceptives, branded opioids (as a safety issue), use of medicines recommended by AWMSG, use of medicines not endorsed by AWMSG.

The group were informed about work being undertaken by CHM regarding drugs that should not be prescribed generically.

The Chairman then asked for volunteers to form a working group to look at the National Indicators for 2012/13. The following members volunteered:

Jonathan Simms  
Rick Greville
John Terry
Sue Jeffs
Sean Young

**ACTION**

WMP to convene Task and Finish group meeting to develop draft recommendations for National indicators 2012/13

13. **CEPP Review – Incentive Schemes**

Members provided an update from each health board and confirmed that the CEPPs were continuing for 2011/12 in their regions, hence retaining the educational and quality components of prescribing incentives. Cardiff and Vale and Powys arrangements were not known.

14. **CEPP Review – National Audits**

The Chairman noted that the National Audit on NSAIDs was in its second year and the National Audit on PPIs had run for one year. The group were asked for suggestions for 2012/13. A number of suggestions were made and it was agreed that members would submit a brief proposal on the following

- Lithium – Fiona Walker
- Repeat Prescribing Systems - Susanna Jacks & Jonathan Simms
- Depression - Sean Young & Sara Isaac
- Antipsychotics in patients with dementia – Fiona Walker
- Stopping medicines - Jamie Hayes
- Appropriate prescribing of ezetimibe [Action from discussion Item 16]

Antimicrobials may be an option pending the outcome of the proposed task and finish group. Jamie Hayes recommended that any suggested audits be discussed with WG first, to avoid duplication.

**ACTION**

Outline and criteria to be forwarded to the Chairman by 12th August 2011

15. **Lipid Prescribing**

The Chairman gave a brief update and Sarah Isaacs gave a verbal update regarding work due to be published imminently by NICE. The group discussed a draft document noting prescribing data and key messages to support the lipid indicator, suitable for primary and secondary care.

16. **Ezetimibe Audit**

A review of ezetimibe prescribing was provided to members for comment. The document was welcomed by the group. The paper included the following recommendations:

- Improve documentation on GP systems of adverse reactions to statins
- Ensure prescribing is consistent with NICE guidance
- Develop joint guidelines with specialists. It was noted that this is under development in North Wales.

The Director of ABPI Wales relayed concerns of the manufacturer regarding content. The Chairman informed members that the audit had been provided to AWPAG for information purposes and was not under consideration by AWMSG. It was agreed that the criteria for the audit could be considered as a national audit for 2012/13.
ACTION
Process for wider consultation of AWPAG papers to be developed before next meeting
Audit criteria to be sent to Chairman by 12th August 2011

17. Welsh Interface Pharmacists Group
The minutes of the meeting held on 1st July 2011 were presented and briefly discussed. There following issue was raised:

- **Shared Care Criteria – ferric carboxymaltose (Ferinject)**
  The WMP Programme Director informed the group that the table used was created by WMP to assess the suitability for shared care for all medicines appraised by AWMSG. The Chair noted the need to adhere to due process and outlined the variations in opinion to date regarding prescribing status of this medicine. The criteria were discussed and the following recommendation to WMP suggested: ferric carboxymaltose should not routinely be suitable for shared care (review 2 years).

**Shared Care Wording**
The recommended wording for shared care was discussed and the following was agreed to be proposed to WMP:

- **a. Suitable for prescribing by all prescribers**
  Suitable for prescribing by all prescribers within their competency. A shared care agreement is not required.

- **b. Suitable for use in Wales prescribed under specialist recommendation**
  Medication is initiated by specialists* with subsequent prescribing and monitoring by GPs. First dose may be prescribed by GP or specialist team.
  **With restriction** the first dose must be prescribed by the specialist team.

- **c. Suitable for prescribing in Wales with a shared care agreement**
  Medication is initiated by specialists*. Monitoring and prescribing is according to an agreed shared care protocol. GP agreement should be requested by the specialist team.

- **d. Suitable for specialist* only prescribing**
  All prescribing, supply and monitoring is undertaken by the specialist team.

*Specialist implies specialist team or GP with special interest (GPwSI) with appropriate accreditation from the specialist faculty.

**ACTION**
Agreed wording to be discussed with WMP and present at AWMSG Steering Committee

18. Feedback from other meetings

**Medicines Management Programme Board**
There were no issues of note.

**All Wales Chief Pharmacists Group**
Jonathan Simms provided a brief verbal update.
PSU Users Group
There were no issues of note.

18. **Papers for Information**
The following paper was circulated for information but not subject to discussion:

- AWMSG Recommendation Wording

19. **Any Other Business**
**Guidance on Adverse Reactions – Company Responsibilities**
The Director of ABPI Wales informed the group that ABPI had recently produced a document concerning company responsibilities when dealing with reported adverse reactions to medicines

**ACTION**
Rick Greville to produce a summary for distribution

**Diabetes Forum**
AWPAG representation on the forum had previously been agreed but not enacted.

**ACTION**
WMP to raise with WG

**Date of next meeting – Thursday, 6th October 2011 at the St Michaels Conference Centre, Abergavenny.**